Health Care–Associated Infections
A Meta-analysis of Costs and Financial Impact on the US Health Care System

Eyal Zimlichman, MD, MSc; Daniel Henderson, MD, MPH; Orly Tamir, PhD, MSc, MHA; Calvin Franz, PhD; Peter Song, BSE; Cyrus K. Yamin, MD; Carol Keohane, BSN, RN; Charles R. Denham, MD; David W. Bates, MD, MSc

IMPORTANCE  Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. Better evaluation of the costs of these infections could help providers and payers to justify investing in prevention.

OBJECTIVE  To estimate costs associated with the most significant and targetable HAIs.

DATA SOURCES  For estimation of attributable costs, we conducted a systematic review of the literature using PubMed for the years 1986 through April 2013. For HAI incidence estimates, we used the National Healthcare Safety Network of the Centers for Disease Control and Prevention (CDC).

STUDY SELECTION  Studies performed outside the United States were excluded. Inclusion criteria included a robust method of comparison using a matched control group or an appropriate regression strategy, generalizable populations typical of inpatient wards and critical care units, methodologic consistency with CDC definitions, and soundness of handling economic outcomes.

DATA EXTRACTION AND SYNTHESIS  Three review cycles were completed, with the final iteration carried out from July 2011 to April 2013. Selected publications underwent a secondary review by the research team.

MAIN OUTCOMES AND MEASURES  Costs, inflated to 2012 US dollars.

RESULTS  Using Monte Carlo simulation, we generated point estimates and 95% CIs for attributable costs and length of hospital stay. On a per-case basis, central line–associated bloodstream infections were found to be the most costly HAIs at $45,814 (95% CI, $30,919–$65,245), followed by ventilator-associated pneumonia at $40,144 (95% CI, $36,286–$44,220), surgical site infections at $20,785 (95% CI, $18,902–$22,667), Clostridium difficile infection at $11,285 (95% CI, $9,118–$13,574), and catheter-associated urinary tract infections at $8,96 (95% CI, $6,03–$11,89). The total annual costs for the 5 major infections were $9.8 billion (95% CI, $8.3–$11.5 billion), with surgical site infections contributing the most to overall costs (33.7% of the total), followed by ventilator-associated pneumonia (31.6%), central line–associated bloodstream infections (18.9%), C difficile infections (15.4%), and catheter-associated urinary tract infections (<1%).

CONCLUSIONS AND RELEVANCE  While quality improvement initiatives have decreased HAI incidence and costs, much more remains to be done. As hospitals realize savings from prevention of these complications under payment reforms, they may be more likely to invest in such strategies.

Published online September 2, 2013.

Copyright 2013 American Medical Association. All rights reserved.
A
some of the most common sources of preventable harm, health care–associated infections (HAIs) represent a major threat to patient safety.1,2 Recent estimates of the national morbidity and mortality burden of HAIs have made it clear that HAIs represent a major public health problem.3 Furthermore, a robust body of evidence exists describing interventions that can substantially reduce the incidence of HAIs,4 and recent analyses indicate that at least 50% are preventable.5,6 Standard-setting organizations such the National Quality Forum have identified HAIs as a key area of focus for patient safety with the development of a number evidence-based, HAI-specific safe practices.7 As a target for those seeking to improve care in the United States, HAIs represent a key opportunity to save lives and reduce costs.1,2,5,9

However, despite the availability of solutions, the strong ethical case for improvement, and the intuitive argument that saving lives ought to save money, large-scale progress against HAIs has been slow. Only recently have health care organizations begun to achieve successes and overcome doubts about the scalability of pilot studies and vanguard institutions. Along with leadership of patient safety professionals, an important driver of progress is the move by payers to deny reimbursement for health care related to preventable harm.10,11 By placing the costs of HAIs with hospitals, this shift has accentuated the fiscal case for prevention.

We believe that better evaluation of the costs of HAIs could help providers and payers justify investing in this area. In addition, for policymakers, sound estimates of the potential systemwide cost savings could mobilize the resources needed to catalyze progress in the cause of improving care and restraining rising health care costs. The purpose of this study was to generate estimates of the costs associated with the most significant and targetable HAIs. To do this, we compiled examinations of the costs of HAIs into robust, precise, broadly applicable estimates of each HAI and also estimated the aggregate annual costs of infections in adults acquired in the inpatient setting.

Methods

To estimate the impact of HAIs on the US health care system, we performed 3 steps. First, we estimated epidemiologic and economic parameters for each main infection type (namely, incidence rates, attributable costs, and added length of hospital stay). Second, we modeled the variation of these outcomes within a large population of patients. And third, we used simulation to extrapolate totals for the US health care system. Because key data were not available for all HAIs, we focused on the 5 with the highest impact on the health care system, that is, the most common, costly, preventable, and well-tracked infections in hospitalized patients. On this basis, surgical site infection (SSI), central line–associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI), ventilator–associated pneumonia (VAP), and Clostridium difficile infection (CDI) were chosen. Methicillin-resistant Staphylococcus aureus (MRSA) is presented as a subcategory where applicable.

Estimation of HAI Incidence

We opted to rely on a single source for HAI incidence estimates: the National Healthcare Safety Network (NHSN) of the Centers for Disease Control and Prevention (CDC), formerly called the National Nosocomial Infections Surveillance (NNIS). The NHSN regularly collects data on the major device-associated and procedure-associated HAIs across a network of 1700 reporting sites (www.cdc.gov/nhsn/about.html). Compared with stand-alone investigations, the NHSN offers superior robustness to regional variation, more current figures amidst epidemiologic fluctuations, and greater methodologic consistency. Using 2009 NHSN data (chosen for concordance with hospital care data described herein), incidence rates for CLABSI, CAUTI, and VAP were estimated as the number of infections per total patient-days and stratified between critical care units and inpatient wards. For SSI and MRSA incidence calculations, 2008 NHSN data were used, which were the most current available. Since NHSN does not yet provide reporting data for CDI, these were estimated from high-quality studies obtained through systematic review. The body of literature used to estimate HAI impacts was found to draw almost entirely on adult populations, and it was believed that results could not be generalized further, and so for all incidence calculations, pediatric and neonatal units were excluded. Long-term acute care settings, whose patients were believed to differ significantly from hospital inpatients by demographics, health status, payer mix, and type of care received, were similarly excluded.

Literature Review for Estimation of Attributable Resource Utilization

To obtain the best available estimates of the key HAI parameters, a systematic review of the literature was conducted, following previously published methods.1,4,8,12 Searches were conducted through PubMed using medical subject headings (MeSH). For specific search strategies, see eTable 1 in the Supplement. The first pass was limited to listings published in English between 1986 and April 2013 with abstracts for review. Abstracts were next eliminated if the study was conducted outside of the United States, since epidemiology, medical practice, and health care economics vary widely internationally, or if they indicated no relevance to the research question. Full-text reviews were performed on the remaining articles. Inclusion was determined on the basis of criteria believed to indicate highly informative sources, specifically (1) robust comparison using either a matched control group or an appropriate regression strategy; (2) generalizable populations typical of inpatient wards and critical care units; (3) methodologic consistency with CDC definitions; and (4) soundness of handling economic outcomes. Review article bibliographies were scanned for potentially useful primary references. Three review cycles were completed, with the last iteration carried out from July 2011 to April 2013.

The research team then undertook a secondary review of selected publications to determine whether articles on the borders fit the inclusion criteria. This process eliminated a large proportion of articles, typically because economic outcomes were considered only secondarily. Even among included ar-
Sensitivity Analysis of Costs and Resource Utilization
The literature review resulted in a point estimate of incremental cost savings and length of stay (LOS). Each measure was calculated as a weighted average of the point estimate from each study selected for inclusion; each study was weighted by its relative sample size. We then conducted a Monte Carlo simulation to develop confidence intervals (CIs) around each point estimate. We chose the Monte Carlo simulation to estimate CIs for its ability to provide relatively realistic estimates of uncertainty. This was important owing to the variety of sources and measures used in the studies included in the analysis.

For the Monte Carlo simulation, we used a variant of the approach described by Jha et al to develop CIs for such measures. For each acceptable study, we simulated a distribution then pooled the results, weighting by sample size. The approach described by Jha et al is essentially dependent on 3 observations: the point estimates for the studies composing the best measure of central tendency and lower and upper bounds. This allows us to include as many studies as we determine are appropriate for inclusion. There was 1 exception to our weighting method: in the case of SSI, a single very large database study would have obviated the findings of others if pooled only by size. Therefore, we separately pooled the smaller studies by sample size and weighted the small sample size pool equally with the result of the large study.

For each parameter of interest for each HAI (ie, cost of SSI; LOS for SSI) we first fit a triangular distribution for each of the relevant published studies based on the reported measures of central tendency and dispersion. In general, we used the 95% CI, if it was either reported in the article or could be calculated from the article, to set the end points for the distribution so that 2.5% of the distribution fell below the lower value and above the upper value. We then set the most likely value of the triangular distribution equal to the published central tendency measure and checked to determine if the modeled triangular distribution reasonably matched the study results. In some cases, we found that the distribution was heavily skewed because the mean value of the triangular distribution differed from the study mean by more than 10%. In these cases, we adjusted for the skewness by fitting a general distribution in which the distribution was piecewise adjusted to shift the density of the probability function to account for the underlying asymmetry.

Finally, for each HAI, we simulated 100 000 sample draws from the modeled distribution for each relevant study simultaneously. At each iteration, we calculated the weighted average of the included studies. We reported the mean and 95% CI from the resulting distribution of those 100 000 weighted averages for each HAI. This approach eliminated the need to rely on normally distributed data and facilitated inclusion of studies that would otherwise be difficult to combine (eg, those reporting means and others reporting medians).

Monte Carlo simulations were conducted using the Monte Carlo simulation software @RISK, version 5.5 (Palisade Corp).

Estimation of National Impact
To determine the financial impact of HAIs on the US health care system, the 2009 National Inpatient Sample (NIS) of the Health Care Utilization Project (HCUP) was used to estimate population exposure (ie, total patient-days or total procedures). The NIS 2009 is the largest publicly available all-payer inpatient database in the United States, holding data on 7.8 million stays from 1050 hospitals in 44 states where 96% of the population resides. The data set approximates a 20% stratified sample of US community hospitals, allowing calculation of national estimates. Since the NIS reports incidence rates for both intensive care units (ICUs) and inpatient wards, to calculate national estimates, we used an overall ratio of 1 to 7 for critical care to inpatient ward days, as used previously. The total incidence of SSI was calculated from total numbers of ICD-9-coded procedures (International Classification of Diseases, Ninth Revision) involving surgical sites. To avoid double counting of separately billed procedures comprising a single actual operation, we counted multiple procedures within a record that are commonly associated with a single surgical site (eg, colectomy and appendectomy, as determined by a physician reviewer) as one if they occurred on the same calendar day. From total patient-days and patient-procedures, using the above described incidence rates and estimates of attributable cost and LOS for each HAI, we generated point and interval estimates for impacts at the national level.

Results
We identified 26 studies providing reasonably robust estimates of attributable costs and/or LOS for the 6 HAIs of interest (Figure). For more detail on studies included, see eTable 2 in the Supplement. For SSIs, we identified 12 studies based on our search strategy and 1 more that dealt specifically with MRSA SSIs. For CLABSI, we identified 4 studies and another study specifically dealing with MRSA bloodstream infections. We identified 4 studies for VAP, while for CDI, 2 were identified. For CAUTI, 2 studies were found for estimating cost but we were unable to find any studies that met our criteria for estimating the attributable LOS. For CLABSI and VAP, estimates were available for LOS specific to both the ICU and for the total hospital stay. For other studies, we were not able to provide separate estimations for both ICU stay and non-ICU stay. We estimated the incidence rate for CDIs based on 3 studies identified through our literature review.

Using Monte Carlo simulation techniques, we generated point estimates and 95% CIs for both costs and LOS (Table 1).
On a per-case basis, CLABSI was found to be the most costly HAI, at $45,814 (95% CI, $30,919-$65,245). CLABSI cases caused by MRSA resulted in even higher associated costs to hospitals ($58,614 [95% CI, $16,760-$174,755]). Similarly, both CLABSI and SSI cases caused by MRSA resulted in the highest attributable excess LOS (15.7 and 23.0 days, respectively).

In 2009, approximately 34.7 million adults received inpatient care in America's hospitals, totaling 165.1 million patient-days. These patients were treated with invasive medical devices during 96.2 million days of care and underwent approximately 8 million operations, all of which placed them at risk for HAIs. The estimated hospitalized adult populations at risk per HAI are reported in Table 2. On an annual basis, SSI (n = 158,639) and CDI (n = 133,657) were estimated to be the most frequent HAIs nationwide (36.0% and 30.3%, respectively) (Table 2). In decreasing frequency were CAUTI (17.4%), CLABSI (9.2%), and VAP (7.1%). From the per-case costs, the aggregate incidence rates, and the population at risk, the cumulative annual costs to the health care system were determined (Table 3). In total, annual costs for the 5 major HAIs was $9.8 billion (95% CI, $8.3-$11.5 billion), with SSIs contributing the most to overall costs (33.7% of the total). Notably, CAUTIs accounted for only 0.3% of the total costs. VAP accounted for 31.7%; CLABSI, 18.9%; and CDI, 15.4%.

**Discussion**

More than a decade since the landmark report *To Err Is Human* brought patient safety to the fore, US hospitals remain less safe than they should be. Hospital-acquired infections account for a large proportion of the harms caused by health care and high

---

**Table 1. Estimates of Costs and LOS Attributed to the 5 Major Health Care–Associated Infections for the US Adult Inpatient Population at Acute Care Hospitals**

<table>
<thead>
<tr>
<th>Health Care–Associated Infection Type</th>
<th>Cost, 2012 $US (95% CI)</th>
<th>LOS (as Total, ICU, d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical site infections</td>
<td>20,785 (18,902-22,667)</td>
<td>11.2 (10.5-11.9)</td>
</tr>
<tr>
<td>MRSA</td>
<td>42,300 (40,005-82,670)</td>
<td>23.0 (14.3-31.7)</td>
</tr>
<tr>
<td>Central line-associated bloodstream infections</td>
<td>45,814 (30,919-65,245)</td>
<td>10.4, 6.9 (6.9-15.2, 3.5-9.6)</td>
</tr>
<tr>
<td>MRSA</td>
<td>58,614 (16,760-174,755)</td>
<td>15.7 (7.9-36.5)</td>
</tr>
<tr>
<td>Catheter-associated urinary tract infections</td>
<td>896 (603-1189)</td>
<td>NR</td>
</tr>
<tr>
<td>Ventilator-associated pneumonia</td>
<td>40,144 (36,284-44,220)</td>
<td>13.1, 8.4 (11.9-14.3, 7.8-9.0)</td>
</tr>
<tr>
<td><em>Clostridium difficile</em> infections</td>
<td>11,285 (9118-13,574)</td>
<td>3.3 (2.7-3.8)</td>
</tr>
</tbody>
</table>

Abbreviations: ICU, intensive care unit; LOS, length of hospital stay; MRSA, methicillin-resistant *Staphylococcus aureus*; NR, not reported.

* Data are reported as mean (95% CI) values.
* Estimates obtained from literature and 100,000-trial Monte Carlo simulations using triangular distribution.
* Estimates obtained from literature and 100,000-trial Monte Carlo simulations using general distribution.
rates of morbidity, mortality, and costs. We estimated that there are approximately 440,000 of these infections annually among US adult inpatients and that their annual costs are $9.8 billion. Over a third of these costs are attributable to SSIs, with a quarter due to VAPs, CAUTIs.

These figures are in many cases lower than previous estimates, which have placed the yearly number of HAIs around 1.7 million and the costs at between $20 billion and $40 billion. These discrepancies arise from both methodological differences and differences in epidemiology. Methodologically, whereas the prior studies sought to examine all HAIs, our focus was on the 5 most important ones with the highest presumed targetable impact. Our focus on adult inpatients only also contributes to the difference. While Klevens et al included pediatric inpatients in estimating incidences, we excluded this group for 2 reasons. First, we found the evidence on HAI costs in pediatric populations to be insufficient for robust cost modeling. Second, we believe that the data from adult populations could not be generalized to children, particularly to the approximately 3 million generally healthy newborns. A large part of the differences in estimates is also due to the lower incidences of infections, in turn, likely due to the success of widespread quality-improvement efforts. While CLABSI is most notable, where infection rates appear to have decreased more than 50%, similar trends have also been observed for other HAIs.

Reported evidence over the last decade shows that major progress has been made in preventing specific types of HAIs, which at one time were viewed as a largely unavoidable risk of care. In a recent systematic review, the authors estimated that as many as 65% to 70% of CLABSIs and CAUTIs and 55% of cases of VAP and SSI are preventable with current evidence-based interventions. In a retrospective medical chart review study performed at 10 hospitals, Landrigan et al estimated that more than 75% of HAIs identified were preventable. Applying these rates to our national cost estimates translates into potential cost savings of $5.0 billion to $5.5 billion annually, which hospitals could still tap into. Thus, implementation of readily available strategies has the potential to produce significant bottom-line savings to hospitals.

For financial incentives to drive improvement in quality and safety of care, hospitals will want to know how much of these potential cost savings would actually contribute to bottom-line savings. Under fee-for-service payment systems and Medicare’s traditional diagnosis-related groups (DRGs) system that allow reclassifying to a higher DRG when complications are assumed, these potential cost savings would actually contribute to bottom-line savings. Under fee-for-service payment systems and Medicare’s traditional diagnosis-related groups (DRGs) system that allow reclassifying to a higher DRG when complications are assumed, these potential cost savings would actually contribute to bottom-line savings. Under fee-for-service payment systems and Medicare’s traditional diagnosis-related groups (DRGs) system that allow reclassifying to a higher DRG when complications are assumed, these potential cost savings would actually contribute to bottom-line savings. Under fee-for-service payment systems and Medicare’s traditional diagnosis-related groups (DRGs) system that allow reclassifying to a higher DRG when complications are assumed, these potential cost savings would actually contribute to bottom-line savings. Under fee-for-service payment systems and Medicare’s traditional diagnosis-related groups (DRGs) system that allow reclassifying to a higher DRG when complications are assumed, these potential cost savings would actually contribute to bottom-line savings.

---

**Table 1. Epidemiology of Health Care–Associated Infections Among US Adult Inpatients (Including ICUs) at Acute Care Hospitals, 2009**

<table>
<thead>
<tr>
<th>Health Care–Associated Infection Type</th>
<th>Incidence Rate</th>
<th>Population at Risk</th>
<th>Cumulative Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical site infections</td>
<td>1.98</td>
<td>8,020,658</td>
<td>158,639</td>
</tr>
<tr>
<td>MRSA</td>
<td>0.29</td>
<td>8,020,658</td>
<td>23,417</td>
</tr>
<tr>
<td>Central line–associated bloodstream infections</td>
<td>1.27</td>
<td>31,695,922</td>
<td>40,411</td>
</tr>
<tr>
<td>MRSA</td>
<td>0.21</td>
<td>31,695,922</td>
<td>66,38</td>
</tr>
<tr>
<td>Catheter-associated urinary tract infections</td>
<td>1.87</td>
<td>41,115,000</td>
<td>77,079</td>
</tr>
<tr>
<td>Ventilator–associated pneumonia</td>
<td>1.33</td>
<td>23,392,785</td>
<td>31,130</td>
</tr>
<tr>
<td>Clostridium difficile infections</td>
<td>3.85</td>
<td>34,716,079</td>
<td>133,657</td>
</tr>
<tr>
<td>Total health care–associated infections</td>
<td>NA</td>
<td>NA</td>
<td>440,916</td>
</tr>
</tbody>
</table>

**Table 2. Total Attributable Financial Impacts of Health Care–Associated Infections in US Adult Inpatients at Acute Care Hospitals, 2009**

<table>
<thead>
<tr>
<th>Health Care–Associated Infection Type</th>
<th>Costs</th>
<th>Total</th>
<th>Lower Bound</th>
<th>Upper Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>9,779,171,077</td>
<td>8,282,405,811</td>
<td>11,492,191,220</td>
<td></td>
</tr>
<tr>
<td>Surgical site infections</td>
<td>3,297,285,451</td>
<td>2,998,570,584</td>
<td>3,595,841,680</td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>990,539,052</td>
<td>93,785,080</td>
<td>1,935,883,296</td>
<td></td>
</tr>
<tr>
<td>Central line–associated bloodstream infections</td>
<td>1,851,384,347</td>
<td>1,249,464,195</td>
<td>2,636,608,279</td>
<td></td>
</tr>
<tr>
<td>MRSA</td>
<td>389,081,519</td>
<td>111,253,391</td>
<td>1,160,029,019</td>
<td></td>
</tr>
<tr>
<td>Catheter-associated urinary tract infections</td>
<td>27,884,193</td>
<td>18,765,813</td>
<td>37,002,574</td>
<td></td>
</tr>
<tr>
<td>Clostridium difficile infections</td>
<td>1,508,347,070</td>
<td>1,218,707,008</td>
<td>1,814,293,587</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3. Meta-analysis of Health Care–Associated Infections**

<table>
<thead>
<tr>
<th>Health Care–Associated Infection Type</th>
<th>Incidence Rate</th>
<th>Population at Risk</th>
<th>Cumulative Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical site infections</td>
<td>1.98</td>
<td>8,020,658</td>
<td>158,639</td>
</tr>
<tr>
<td>MRSA</td>
<td>0.29</td>
<td>8,020,658</td>
<td>23,417</td>
</tr>
<tr>
<td>Central line–associated bloodstream infections</td>
<td>1.27</td>
<td>31,695,922</td>
<td>40,411</td>
</tr>
<tr>
<td>MRSA</td>
<td>0.21</td>
<td>31,695,922</td>
<td>66,38</td>
</tr>
<tr>
<td>Catheter-associated urinary tract infections</td>
<td>1.87</td>
<td>41,115,000</td>
<td>77,079</td>
</tr>
<tr>
<td>Ventilator–associated pneumonia</td>
<td>1.33</td>
<td>23,392,785</td>
<td>31,130</td>
</tr>
<tr>
<td>Clostridium difficile infections</td>
<td>3.85</td>
<td>34,716,079</td>
<td>133,657</td>
</tr>
<tr>
<td>Total health care–associated infections</td>
<td>NA</td>
<td>NA</td>
<td>440,916</td>
</tr>
</tbody>
</table>

**Abbreviations:** ICU, intensive care unit; MRSA, methicillin-resistant *Staphylococcus aureus*; NA, not applicable.


*b* Incidence rate in cases per 100 patient procedures; population at risk in total patient procedures.

*c* Incidence rate in cases per 1000 device-days; population at risk in total device-days.

*d* Incidence rate in cases per 1000 patient-days; population at risk in total patient-days.

---

These figures are in many cases lower than previous estimates, which have placed the yearly number of HAIs around 1.7 million and the costs at between $20 billion and $40 billion. These discrepancies arise from both methodological differences and differences in epidemiology. Methodologically, whereas the prior studies sought to examine all HAIs, our focus was on the 5 most important ones with the highest presumed targetable impact. Our focus on adult inpatients only also contributes to the difference. While Klevens et al included pediatric inpatients in estimating incidences, we excluded this group for 2 reasons. First, we found the evidence on HAI costs in pediatric populations to be insufficient for robust cost modeling. Second, we believe that the data from adult populations could not be generalized to children, particularly to the approximately 3 million generally healthy newborns. A large part of the differences in estimates is also due to the lower incidences of infections, in turn, likely due to the success of widespread quality-improvement efforts. While CLABSI is most notable, where infection rates appear to have decreased more than 50%, similar trends have also been observed for other HAIs.

Reported evidence over the last decade shows that major progress has been made in preventing specific types of HAIs, which at one time were viewed as a largely unavoidable risk of care. In a recent systematic review, the authors estimated that as many as 65% to 70% of CLABSIs and CAUTIs and 55% of cases of VAP and SSI are preventable with current evidence-based interventions. In a retrospective medical chart review study performed at 10 hospitals, Landrigan et al estimated that more than 75% of HAIs identified were preventable. Applying these rates to our national cost estimates translates into potential cost savings of $5.0 billion to $5.5 billion annually, which hospitals could still tap into. Thus, implementation of readily available strategies has the potential to produce significant bottom-line savings to hospitals.
tions occur, hospitals formerly had little financial incentive to prevent infections. However, Medicare’s nonpayment policy for treatment of largely preventable in-hospital conditions, launched in 2006 and amended in 2008, sought to change that. This policy currently translates prevention of CLABSIs, CAUTIs, and certain SSIs into cost savings for hospitals treating Medicare and Medicaid patients.53 Even this has been criticized as not going far enough to drive either patient safety or substantial cost savings.54 Indeed, under a new Centers for Medicare & Medicaid Services (CMS) rule that authorizes states to identify other provider-preventable conditions for which Medicaid payment will be prohibited,55 and with emerging payment reforms, hospitals should see financial benefits from preventing HAIs.

Since SSIs constitute the largest portion of HAI-related costs nationally, and since less progress has been made in preventing these infections than in other areas of care, research and quality improvement efforts are clearly needed in this area. In addition, policy efforts must also target SSIs. This might be achieved by increasing federal support to evaluate effectiveness of HAI prevention approaches, encouraging innovation to expand the list of effective interventions, or enhancing surveillance programs to include post discharge tracking of SSIs. While enhancing our ability to prevent SSIs, CMS could expand the list of procedures for which it will not reimburse for a higher-charge DRG due to SSIs and encourage private payers to implement nonpayment strategies. However, it should be noted that the consequences of such policies have not been fully evaluated, and there is a need to assess whether these initiatives might have substantial unintended effects.

Our study has several limitations. First, we based our cost estimates on published studies that used heterogeneous methods to assess attributable costs, sometimes using older data. Though a stringent review process sought to mitigate this limitation, some heterogeneity was inevitable. Indeed, for some HAIs, we had to exclude all available sources. Additionally, we used Monte Carlo simulation as an attempt to account for the heterogeneity and uncertainty in our probabilistic analysis. The paucity of high-quality studies that would assess the costs and excess LOS associated with CAUTI and CDI suggest a clear need for further research.

It is also likely that our results contain some underestimations. One such underestimation might result from the tradeoff between consistency and sensitivity in our decision to rely on NHSN data only. SSIs provide a clear example of this in that many become evident after discharge and are thus not captured within the NHSN surveillance programs. Still, the NHSN program provides the largest data source for real-life HAI rates and has clear benefits over relying on more vigilant published reports from single institutions. Another source of potential underestimation is related to the patient population in this study. Our report is limited to HAIs in the adult inpatient population, excluding not only neonatal and pediatric patients but also patients in non–acute-care facilities such as long-term care and dialysis centers. Total incidence and national HAI-attributable cost estimations for the entire health care system are likely much higher, and if this is the case, a recommendation to increase quality improvement initiatives would be even more applicable.

Finally, we acknowledge that there is a variety of factors, such as comorbidity and other acute conditions, that may contribute to infections. Although comorbidities and primary diagnosis were accounted for in the included studies, it is obvious that this was not a complete list.

In summary, our study provides updated, robust, and applicable estimates for resources attributable to the major HAIs that continue to plague modern health care systems and create considerable harm to patients. While widespread quality improvement initiatives have resulted in a decrease in HAIs incidence, much more remains to be done. These estimates may be used for business case development to support investment in HAI reduction efforts. Investment in leadership, practices, and technologies will continue to drive patient safety and allow hospitals to realize cost savings attributed to prevention of HAIs. Ongoing payment reforms such as value-based purchasing coupled with incentives to reduce the frequency of these events should drive local, state, and federal efforts and bring about substantial reduction in patient harm.
REFERENCES

Pay for Preventing (Not Causing) Health Care–Associated Infections

Mitchell H. Katz, MD

The reason to prevent health care–associated infections is to save lives, not costs. Readers might wonder then why we thought it was important to publish a systematic review of the costs of health care–associated infections.

The answer is that the editors believe that the extraordinary costs of these infections—an estimated $10 billion a year in the United States—will motivate health care administrators to invest in the necessary systems to decrease these infections. The costs of these investments are not trivial. Information technology systems to monitor infection rates (successful quality improvement projects require knowledge of baseline rates of infection and infection following interventions); dedicated time to educate clinicians; supplementary assessments of patients for need of lines, catheters, or ventilator support; and preventive measures (eg, chlorhexidine baths, oral care with antiseptic solution) are costly. This study, however, will enable hospital administrators to better prioritize their spending by allowing them to compare the costs of interventions with the savings accrued by avoiding infections.

In the past, one of the challenges in motivating system change through demonstrating the costs of health care–associated infections was that insurers paid hospitals for the additional costs owing to the infection. Under this perverse payment scheme, a hospital that invested money to decrease infections would pay “twice”: once for the intervention and once through not getting the additional money for treating the patient for the additional complication. This began to change in 2009 when Medicare stopped paying for hospital-acquired infections.

Not paying for hospital-acquired infections or errors is an important part of the movement toward paying for quality, not quantity, of care. As physicians, we should embrace the opportunity that these new payment schemes offer for bringing higher-quality care—including fewer infections—to our patients.